Immunovant (NASDAQ: IMVT)
Immunovant Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immunovant Company Info
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
News & Analysis
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof.
Why Shares of Immunovant Are Soaring on Tuesday
Immunovant sees strong potential for an autoimmune disorder therapy.
These 2 Biotech Stocks Are Bucking a Down Market Tuesday
Stock index futures pointed to a lower open on Wall Street Tuesday morning.
Why Immunovant Stock Is Skyrocketing This Week
The drugmaker announced a $75 million public offering.
Why Shares of Immunovant Are Down Almost 10% This Afternoon
An analyst note is extending yesterday's sell-off.
Why Shares of Immunovant Are Tanking Today
Shareholders are throwing in the towel after not getting the deal they were expecting.
Why Immunovant Stock Is Soaring Today
The company could get a buyout offer soon.
Why Immunovant Stock Is Bouncing Back Today
The company is finally getting a break after a rough past couple of weeks.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.